Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome

3 September 2026 · By · Wire by Fusion42

Published

3 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at ir.ultragenyx.com →

◆ Verified

Fusion42 · 3 September 2026 · Fusion42 review

Ultragenyx announced that its Phase 3 Aspire trial for apazunersen in Angelman syndrome failed to meet primary and key secondary efficacy endpoints, leading the company to reconsider the program and reduce expenses while focusing on its commercial business and other pipeline candidates.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You must rethink your rare disease program if apazunersen’s failure shakes market confidence in Angelman treatments, while focusing on commercialised assets will safeguard cash and support pipeline resilience.

◆ Coverage

1 source · 3 Sep 2026

◆ Related on Wire

◆ Topics

Biotechrare-diseaseclinical-trialangelman-syndromedrug-developmentpipeline-risk